Skip to main content

Omada Health, Inc. (OMDA) Receives a Buy from J.P. Morgan

Tipranks - Tipranks - Sat Nov 15, 2025

In a report released on November 12, Destiny Jackson from J.P. Morgan maintained a Buy rating on Omada Health, Inc., with a price target of $32.00. The company’s shares closed yesterday at $21.45.

Meet Your ETF AI Analyst

According to TipRanks, Jackson is a 2-star analyst with an average return of 10.5% and a 50.00% success rate.

In addition to J.P. Morgan, Omada Health, Inc. also received a Buy from Canaccord Genuity’s Richard Close in a report issued on November 7. However, on November 8, TR | OpenAI – 4o reiterated a Hold rating on Omada Health, Inc. (NASDAQ: OMDA).

See the top stocks recommended by analysts >>

Based on Omada Health, Inc.’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $68.03 million and a GAAP net loss of $3.18 million. In comparison, last year the company earned a revenue of $35.1 million and had a GAAP net loss of $18.97 million

Read More on OMDA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).